A Phase 1/2 Study of CMC-544 Administered in Combination With Rituximab in Subjects With Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Trial Profile

A Phase 1/2 Study of CMC-544 Administered in Combination With Rituximab in Subjects With Follicular or Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 10 Jan 2014 In ClinicalTrials.gov, status is changed recruiting from active, no longer recruiting. But as the end date is nearing, I have not updated it.
    • 04 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top